Study Stopped
There was no change in size of the Nd:YAG laser-treated GCD deposits as assessed by the various modalities on visit 2, and it was decided to terminate the study.
Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) Laser Treatment for Granular Corneal Dystrophy
Treatment of Granular Corneal Dystrophy Using Nd-YAG Laser
1 other identifier
interventional
2
1 country
1
Brief Summary
Granular Corneal Dystrophy is a rare hereditary disease characterized by the development of deposits within the cornea, which may in turn affect the quality of vision. Still today, all existing treatment options are based on surgical intervention and there is no minimally-invasive treatment available for the disease. The goal of this clinical trial is to test the effectiveness and safety of Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser as a minimally-invasive treatment for people suffering from Granular Corneal Dystrophy. The main question it aims to answer is if Nd:YAG laser is able to disintegrate the characteristic corneal depositions in a safe manner without causing significant adverse effects. If found suitable to be part of the study, participants will first undergo a series of imaging studies to measure and characterize the corneal deposits. After completion, the participants will undergo the Nd:YAG laser treatment under local anesthesia by a corneal specialist, targeting deposits not involving the visual axis. Following the treatment, participants might need to take antibiotic eye drops for a duration of approximately one week. The participants will be required to attend two follow-up visits: one week after the treatment and 3 months after the treatment. In each one of the follow-up visits, an eye examination will be performed and the same series of imaging studies that was performed prior to the Nd:YAG laser treatment will be repeated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 26, 2022
CompletedFirst Submitted
Initial submission to the registry
December 23, 2023
CompletedFirst Posted
Study publicly available on registry
January 11, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 9, 2024
CompletedJanuary 9, 2025
January 1, 2025
2.9 years
December 23, 2023
January 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in size of granular corneal deposits due to Nd:YAG laser treatment
The size of each one of the two treated corneal deposits per participant will be measured in µm on images taken by both the AS-OCT and slit-lamp photography in each study visit. The size will be measured both manually and automatically on each one of the imaging techniques. A comparison of the size between study visits will be performed, change from day 7 post-intervention to month 3 post-intervention.
Baseline, Post-intervention day 7, Post-intervention 3 months
Secondary Outcomes (2)
Safety as the number participants experiencing adverse events of inflammation and/or scarring
Post-intervention day 7, Post-intervention 3 months
Safety as the number of participants experiencing decrease in visual acuity
Baseline, Post-intervention day 7, Post-intervention 3 months
Study Arms (1)
Nd:YAG Laser Interventional Cohort
EXPERIMENTALParticipants include Granular Corneal Dystrophy patients. On visit 1, participants will undergo visual acuity testing, slit-lamp examination, intra-ocular pressure (IOP) measurement, Scheimpflug tomography, anterior-segment optical coherence tomography (AS-OCT), and slit-lamp photography of the cornea. On the same visit or on a separate visit within 1 month, the participants will undergo the Nd:YAG Laser treatment. At the investigators' discretion, after the procedure, participants might need to administer generic topical antibiotic eye drops three times daily for a week. One week post-intervention (visit 2), the participant will repeat visual acuity testing, slit-lamp examination, IOP measurement, Scheimpflug tomography, AS-OCT, and slit-lamp photography of the cornea. Three months post-intervention (visit 3), the participant will repeat visual acuity testing, slit-lamp examination, IOP measurement, Scheimpflug tomography, AS-OCT, and slit-lamp photography of the cornea.
Interventions
Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen. After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure.
Eligibility Criteria
You may qualify if:
- Patients older than 18 years of age
- Diagnosis of granular corneal dystrophy with presence of granular opacities in the peripheral cornea of appropriate size (ca. 50 µm) in at least one eye
- Willingness and ability to give signed informed consent and follow study instructions
You may not qualify if:
- Presence of any active intra-ocular inflammation
- Pre-existing glaucoma or retinal edema
- Cannot properly self-administer or receive an eye drop medication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Wilmer Eye Institute - Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
Related Publications (14)
Aron-Rosa D. Use of a pulsed neodymium-Yag laser for anterior capsulotomy before extracapsular cataract extraction. J Am Intraocul Implant Soc. 1981 Fall;7(4):332-3. doi: 10.1016/s0146-2776(81)80029-8. No abstract available.
PMID: 7349647BACKGROUNDFankhauser F, Lortscher H, van der Zypen E. Clinical studies on high and low power laser radiation upon some structures of the anterior and posterior segments of the eye. Experiences in the treatment of some pathological conditions of the anterior and posterior segments of the human eye by means of a Nd:YAG laser, driven at various power levels. Int Ophthalmol. 1982 May;5(1):15-32. doi: 10.1007/BF00129992.
PMID: 7118438BACKGROUNDVogel A, Busch S, Jungnickel K, Birngruber R. Mechanisms of intraocular photodisruption with picosecond and nanosecond laser pulses. Lasers Surg Med. 1994;15(1):32-43. doi: 10.1002/lsm.1900150106.
PMID: 7997046BACKGROUNDJagger JD. The Nd-YAG Laser in Ophthalmology: Principles and Clinical Applications of Photodisruption. Br J Ophthalmol. 1986;70(1):79.
BACKGROUNDBlumenkranz MS. The evolution of laser therapy in ophthalmology: a perspective on the interactions between photons, patients, physicians, and physicists: the LXX Edward Jackson Memorial Lecture. Am J Ophthalmol. 2014 Jul;158(1):12-25.e1. doi: 10.1016/j.ajo.2014.03.013. Epub 2014 Mar 31.
PMID: 24699157BACKGROUNDFicker LA, Steele AD. Complications of Nd:YAG laser posterior capsulotomy. Trans Ophthalmol Soc U K (1962). 1985;104 ( Pt 5):529-32.
PMID: 3863341BACKGROUNDKarahan E, Er D, Kaynak S. An Overview of Nd:YAG Laser Capsulotomy. Med Hypothesis Discov Innov Ophthalmol. 2014 Summer;3(2):45-50.
PMID: 25738159BACKGROUNDMunier FL, Frueh BE, Othenin-Girard P, Uffer S, Cousin P, Wang MX, Heon E, Black GC, Blasi MA, Balestrazzi E, Lorenz B, Escoto R, Barraquer R, Hoeltzenbein M, Gloor B, Fossarello M, Singh AD, Arsenijevic Y, Zografos L, Schorderet DF. BIGH3 mutation spectrum in corneal dystrophies. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):949-54.
PMID: 11923233BACKGROUNDWeiss JS, Moller HU, Aldave AJ, Seitz B, Bredrup C, Kivela T, Munier FL, Rapuano CJ, Nischal KK, Kim EK, Sutphin J, Busin M, Labbe A, Kenyon KR, Kinoshita S, Lisch W. IC3D classification of corneal dystrophies--edition 2. Cornea. 2015 Feb;34(2):117-59. doi: 10.1097/ICO.0000000000000307.
PMID: 25564336BACKGROUNDEllies P, Renard G, Valleix S, Boelle PY, Dighiero P. Clinical outcome of eight BIGH3-linked corneal dystrophies. Ophthalmology. 2002 Apr;109(4):793-7. doi: 10.1016/s0161-6420(01)01025-9.
PMID: 11927442BACKGROUNDSeitz B, Behrens A, Fischer M, Langenbucher A, Naumann GO. Morphometric analysis of deposits in granular and lattice corneal dystrophy: histopathologic implications for phototherapeutic keratectomy. Cornea. 2004 May;23(4):380-5. doi: 10.1097/00003226-200405000-00013.
PMID: 15097134BACKGROUNDLopes-Ferreira D, Neves H, Queiros A, Faria-Ribeiro M, Peixoto-de-Matos SC, Gonzalez-Meijome JM. Ocular dominance and visual function testing. Biomed Res Int. 2013;2013:238943. doi: 10.1155/2013/238943. Epub 2013 Nov 11.
PMID: 24319677BACKGROUNDBhargava R, Kumar P, Prakash A, Chaudhary KP. Estimation of mean ND: Yag laser capsulotomy energy levels for membranous and fibrous posterior capsular opacification. Nepal J Ophthalmol. 2012 Jan-Jun;4(1):108-13. doi: 10.3126/nepjoph.v4i1.5861.
PMID: 22344007BACKGROUNDDrake MV. Neodymium:YAG laser iridotomy. Surv Ophthalmol. 1987 Nov-Dec;32(3):171-7. doi: 10.1016/0039-6257(87)90092-0.
PMID: 3328316BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Albert S Jun, MD, PhD
Wilmer Eye Institute/Johns Hopkins University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DEVICE FEASIBILITY
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 23, 2023
First Posted
January 11, 2024
Study Start
January 26, 2022
Primary Completion
December 9, 2024
Study Completion
December 9, 2024
Last Updated
January 9, 2025
Record last verified: 2025-01